The current research included 70 patients in intensive care units who received either standard care or probiotics twice a day for two weeks. Probiotics are live microorganisms – – popularly called ‘good’ bacteria. Probiotics are thought to boost someone’s resistance to dangerous germs, the experts said. Antibiotic-resistant bacteria colonized the intestines of ten % of individuals who received probiotics and 15 % of these who got standard care. However, this difference was not significant statistically, the researchers noted. The scholarly study was published online Aug. 27 in the journal Infection Control & Hospital Epidemiology. Drug-resistant bacteria pose a significant threat to hospital patients because they raise the risk of hard-to-treat infections that pass on easily, the researchers stated.The contract is in addition to the partnership between your two companies announced in September 2010 in which Reata granted to Abbott distinctive rights to develop and commercialize its lead Goal compound, bardoxolone methyl, outside of the United States, excluding certain Asian marketplaces. The collaboration announced today is usually a global agreement and carries a large number of molecules in a wide selection of therapeutic areas, including pulmonary, central nervous system immunology and disorders. Abbott and Reata will similarly share costs and earnings for all new AIMs in all newly licensed indications aside from rheumatoid arthritis and choose other autoimmune diseases, where Abbott will take 70 % of profits and costs and Reata will take 30 %.